Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DC and NK cells in NSCLC
NCT07202611Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital Clinical Trial Center
- Start
- Dec 2022
- Primary completion
- Sep 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous natural killer cells in non-small cell lung cancer (NSCLC), sponsored by National Taiwan University Hospital Clinical Trial Center. Primary endpoint: Incidence and Severity of Adverse Events at 12 weeks. Started Dec 2022; status: recruiting.
02
Drugs
autologous natural killer cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07202611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202611.